ABBV-637

N/A

Report date: 2023/12/14 17:10:52

Base Information

Drug NameABBV-637
Drug Alias NameABBV-637
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionApoptosis stimulantsApoptosis regulator Bcl-X inhibitorsEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1Apoptosis regulator Bcl-X
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanAustralia +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A